![](/img/cover-not-exists.png)
XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy
Engert, A., Griskevicius, L., Zyuzgin, Y., Lubenau, H., del Giglio, A.Volume:
50
Language:
english
Journal:
Leukemia & Lymphoma
DOI:
10.1080/10428190902756081
Date:
January, 2009
File:
PDF, 236 KB
english, 2009